Pfizer-BioNTech vaccine effectiveness wanes for children 5 to 11, but still protects against serious outcomes, CDC data show - The Washington Post

The research provides an evolving picture of the vaccine’s performance in children, and some experts said it suggested a need to consider increasing the size of the dose 5-to-11-year-olds receive.

The data are broadly consistent with real-world effectiveness data for adults showing that protection from two doses diminishes over time, but that in people eligible for a booster, a third dose revs… [+7615 chars]

full article...